Search research articles
Contact Us
Filters
Showing results (61-70 of 71) with videos related to
Page
of 8
Sort By:
The New England Journal of Medicine
|
February 7, 2024
An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis
Robert Bissonnette, Andreas Pinter, Laura K Ferris, et al.
Journal of the American Academy of Dermatology
|
September 25, 2016
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
Andrew Blauvelt, Kristian Reich, Tsen-Fang Tsai, et al.
Dermatology and Therapy
|
May 16, 2026
Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial
Nada Elbuluk, April W Armstrong, Ronald Vender, et al.
Gastroenterology
|
September 26, 2015
Differences in Colonoscopy Quality Among Facilities: Development of a Post-Colonoscopy Risk-Standardized Rate of Unplanned Hospital Visits
Isuru Ranasinghe, Craig S Parzynski, Rana Searfoss, et al.
Journal of Cutaneous Medicine and Surgery
|
July 11, 2014
A consensus on acne management focused on specific patient features
Charles Lynde, Jerry Tan, Anneke Andriessen, et al.
Journal of Cutaneous Medicine and Surgery
|
March 12, 2019
Checklist for the Systemic Treatment of Psoriasis Using Biologics: A Delphi Study
Christine Fahim, Ben Whan Kim, Marc Bourcier, et al.
JAMA Dermatology
|
February 18, 2026
Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension
Matthias Augustin, Steven R Feldman, Richard B Warren, et al.
Journal of Drugs in Dermatology : JDD
|
October 3, 2013
Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use
Carrie Brodmerkel, Eric Wadman, Richard G Langley, et al.
The British Journal of Dermatology
|
July 25, 2023
Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)
Linda F Stein Gold, Jerry Bagel, Stephen K Tyring, et al.
Dermatology and Therapy
|
December 23, 2018
Clinical Goals and Barriers to Effective Psoriasis Care
Bruce E Strober, Joelle M van der Walt, April W Armstrong, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 71) with videos related to
Sort By:
Page
of 8
The New England Journal of Medicine
|
February 7, 2024
An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis
Robert Bissonnette, Andreas Pinter, Laura K Ferris, et al.
Journal of the American Academy of Dermatology
|
September 25, 2016
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
Andrew Blauvelt, Kristian Reich, Tsen-Fang Tsai, et al.
Dermatology and Therapy
|
May 16, 2026
Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial
Nada Elbuluk, April W Armstrong, Ronald Vender, et al.
Gastroenterology
|
September 26, 2015
Differences in Colonoscopy Quality Among Facilities: Development of a Post-Colonoscopy Risk-Standardized Rate of Unplanned Hospital Visits
Isuru Ranasinghe, Craig S Parzynski, Rana Searfoss, et al.
Journal of Cutaneous Medicine and Surgery
|
July 11, 2014
A consensus on acne management focused on specific patient features
Charles Lynde, Jerry Tan, Anneke Andriessen, et al.
Journal of Cutaneous Medicine and Surgery
|
March 12, 2019
Checklist for the Systemic Treatment of Psoriasis Using Biologics: A Delphi Study
Christine Fahim, Ben Whan Kim, Marc Bourcier, et al.
JAMA Dermatology
|
February 18, 2026
Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension
Matthias Augustin, Steven R Feldman, Richard B Warren, et al.
Journal of Drugs in Dermatology : JDD
|
October 3, 2013
Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use
Carrie Brodmerkel, Eric Wadman, Richard G Langley, et al.
The British Journal of Dermatology
|
July 25, 2023
Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)
Linda F Stein Gold, Jerry Bagel, Stephen K Tyring, et al.
Dermatology and Therapy
|
December 23, 2018
Clinical Goals and Barriers to Effective Psoriasis Care
Bruce E Strober, Joelle M van der Walt, April W Armstrong, et al.
Page
of 8